Avenzo Therapeutics Advances Dual CDK Inhibitor Breast Cancer Study
SAN DIEGO, Calif., April 28, 2026 Avenzo Therapeutics, Inc. has announced the initiation of the combination cohort in its...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SAN DIEGO, Calif., April 28, 2026 Avenzo Therapeutics, Inc. has announced the initiation of the combination cohort in its...
New York, USA | March 17, 2026 Pfizer has announced positive topline results from its Phase 2 FOURLIGHT-1 clinical...
